Today: 9 June 2026
Browse Category

BME:ITX 9 October 2025 - 8 February 2026

IBEX 35 Week Ahead: Spain’s Bolsa de Madrid Outlook After Inditex Record, Naturgy Shock and ECB Countdown (Updated Dec 14, 2025)

IBEX 35 Week Ahead: Spain’s Bolsa de Madrid Outlook After Inditex Record, Naturgy Shock and ECB Countdown (Updated Dec 14, 2025)

Spain’s IBEX 35 closed last week at 16,854.4, up 0.99%, after briefly touching 17,000 points for the first time. Banks led gains, with the IBEX 35 Banks index up 1.39% weekly and 103.39% year-to-date, while energy stocks lagged. Naturgy dropped 8.53% after BlackRock sold a 7.1% stake for €1.7 billion. Markets await ECB signals and year-end flows.
14 December 2025
···
Uzbekistan’s Big Bet: Import Fair 2025 Sparks a ‘Made in Uzbekistan’ Boom

Uzbekistan’s Big Bet: Import Fair 2025 Sparks a ‘Made in Uzbekistan’ Boom

Uzbekistan launched its first international Import Fair in Tashkent, unveiling $8.5 billion in new investment projects to boost local manufacturing and reduce imports. At the same time, 66 Uzbek firms promoted exports at MSV-2025 in Brno. GDP rose 7.2% year-on-year in early 2025, with FDI reaching $11.9 billion in 2024. Major foreign companies, including Inditex, praised recent trade reforms.
9 October 2025
·

Stock Market Today

  • Washington's Railroad Rule Changes Threaten U.S. Supply Chain
    June 9, 2026, 9:15 AM EDT. Congress and the White House are quietly imposing new regulations on U.S. railroads, a critical component of the national economy. These changes, seen as micromanagement, could disrupt freight movement and supply chains. The timing raises concerns amid ongoing economic pressures and recovery efforts post-pandemic. Rail networks handle bulk goods and industrial materials vital to commerce. Industry experts warn that increased federal oversight may hinder operational efficiency and investment. Delays or inefficiencies in rail transport could ripple through markets, affecting costs and delivery times across sectors. Stakeholders urge a balanced approach to regulation to ensure infrastructure resilience without stifling rail companies' flexibility and growth.

Latest articles

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

9 June 2026
Snap Inc. shares fell 1.9% to $5.65, underperforming a rising Nasdaq and leaving the stock 46% below its 52-week high, as investors weigh weak ad revenue growth, North American user declines, and cost-cutting moves against ongoing competitive pressure from Meta and TikTok.
Go toTop